Abstract Subarachnoid hemorrhage (SAH), predominantly caused by a ruptured aneurysm, is a devastating neurological disease that has a morbidity and mortality rate higher than 50 %. Most of the traditional in vivo research has focused on the pathophysiological or morphological changes of large arteries after intracisternal blood injection. This was due to a widely held assumption that delayed vasospasm following SAH was the major cause of delayed cerebral ischemia and poor outcome. However, the results of the CONSCIOUS-1 trial implicated some other pathophysiological factors, independent of angiographic vasospasm, in contributing to the poor clinical outcome. The term early brain injury (EBI) has been coined and describes the immediate injury to the brain after SAH, before onset of delayed vasospasm. During the EBI period, a ruptured aneurysm brings on many physiological derangements such as increasing intracranial pressure, decreased cerebral blood flow, and global cerebral ischemia. These events initiate secondary injuries such as blood-brain barrier disruption, inflammation, and oxidative cascades that all ultimately lead to cell death. Given the fact that the reversal of vasospasm does not appear to improve patient outcome, it could be argued that the treatment of EBI may successfully attenuate some of the devastating secondary injuries and improve the outcome of patients with SAH. In this review, we provide an overview of the major advances in EBI after SAH research.
Introduction
Subarachnoid hemorrhage (SAH) is a common and frequently devastating condition, accounting for 5 % of all stroke types [1] . Each year, approximately 1 in 10,000 North Americans suffer from an aneurysmal SAH, and this carries with it a greater than 50 % combined morbidity and mortality rate [2] . Despite advances in diagnosis and surgical treatment of SAH, effective therapeutic interventions are still limited and clinical outcomes remain disappointing. Traditionally, delayed cerebral vasospasm (CVS) has been considered the single and most important cause of delayed cerebral ischemia and poor outcomes [3] . Although animal studies have found many agents which inactivate spasmogenic substances or block arterial smooth muscle contraction, no agent has brought tremendous improvement in the human patient outcome after SAH. Early brain injury (EBI) was reported as a primary cause of mortality in SAH patients [4] , and many important pathological mechanisms have been recognized to be initiated within minutes after aneurysmal SAH [5] . Recently, intensive research efforts have aimed to reveal the mechanisms of EBI. In this review, we provide an overview of the major advances in EBI after SAH research.
The SAH Experiments Before Early Brain Injury

Experimental Focus on Delayed Cerebral Vasospasm After SAH
Since the first demonstration of CVS, about 60 years ago [6] , many experimental and clinical studies have tried to disclose mechanisms responsible for this persistent vasoconstriction and to find proper treatment for its prevention and/or reversal. In humans, CVS usually occurs on day 3 after SAH, peaks at day 6-8, and lasts for 2-3 weeks [7] . Delayed cerebral ischemia has been considered to be induced by CVS because several studies found a strong association between radiologically confirmed vasospasm and clinical signs of delayed cerebral ischemia [8] [9] [10] . Therefore, there was a widely held assumption that CVS was the major cause of the high mortality and poor outcome after an otherwise successful treatment of a ruptured intracranial aneurysm [11] . Thus, the majority of research performed worldwide has focused on strategies to limit arterial narrowing and delayed cerebral ischemia following SAH [3] . Restoration of narrowed large arteries, using pharmacological agents, was believed to improve vasospasm as a whole. This conclusion was arrived at by using the most common model of SAH and vasospasm, the canine "two-hemorrhage" model, in which two injections of blood, into the dog's basal cistern, are performed 48 h apart in order to observe the large artery pathophysiological or morphological changes [12] .
Translational Trials for Cerebral Vasospasm: from Animals to Humans
Many pathophysiological mediators have been demonstrated in CVS such as (1) the dysfunction of nitric oxide (NO)-nitric oxide synthase (NOS) pathway, (2) endothelin-1, (3) ferrous hemoglobin released from the subarachnoid clot and subsequent oxidative stress, (4) inflammatory pathways, (5) blood-brain barrier (BBB) breakdown by endothelial apoptosis or thrombin, (6) excitotoxicity and membrane pathology of Ca 2+ channels [13, 14] . Numerous interventions are currently being investigated for CVS treatment [15] . Several promising pharmacological treatments, previously demonstrated in pre-clinical animal experiments, have translated to human randomized and blinded clinical trials such as: calcium channel antagonists (nimodipine and nicardipine) [16] [17] [18] [19] , endothelin antagonists [20] [21] [22] , erythropoietin [23] , fasudil [24] , magnesium sulfate [25] , statins [26, 27] , tirilazad [28, 29] , and tissue plasminogen activator [30] . However, most of them failed in clinical trials for prevention and treatment of CVS [31] , except fasudil which is used clinically in Japan and China [32] . Nimodipine had a beneficial effect on the reduction of in morbidity and improvement in functional outcome but not CVS [33] . Therefore, even now patients suffering from CVS receive complex treatments with calcium antagonists (oral nimodipine treatment), hypertensive drugs, hemodilution and hypervolemia (triple H therapy), risky and often only temporarily effective intra-arterial administration of vasodilator drugs, or balloon angioplasty [34] .
The Next Targets for SAH Research After the CONSCIOUS-1 Trial
Clazosentan, a selective endothelin receptor type A antagonist, has been proven effective to decrease CVS after experimental SAH [35] . The patients after SAH treated with clazosentan demonstrated a 65 % relative risk reduction in angiographic vasospasm. However, mortality or clinical outcome was not improved in the CONSCIOUS-1 trail (clazosentan to overcome neurological ischemia and infarction occurring after SAH) [20] . These observations indicate that the pathophysiology underlying delayed cerebral ischemia is multifactorial and that other pathophysiological factors, which are independent of angiographic vasospasm, can contribute to the outcome [36] . Additionally, it may be that the pathological mechanisms, activating within minutes after SAH and leading to EBI, play an important role in the pathogenesis of delayed ischemic injury and poor outcome [37] .
Experiments on Early Brain Injury After SAH
Experimental Transition from Cerebral Vasospasm to Early Brain Injury
The term EBI has been coined as the period which spans from the moment of initial bleeding to the onset of CVS. It describes the immediate injury to the brain after aneurysmal SAH as a whole, reported by Kusaka et al. in 2004 [38] . It can be suggested that the EBI precipitates the occurrence of CVS in many ways, including vascular injury from acute ischemia, inflammation, and blood products, which may result in damage of NO-releasing neurons [39] .
Since the main pathophysiological stage has changed from the large arteries to the brain parenchyma, the experimental modeling of EBI began to simulate the intracranial artery rupture, and the common experimental model changed to the rodent "endovascular puncture" model. This model was independently described by Bederson et al. and Veelken et al. [40, 41] , and the surgical procedure aims to perforate the internal carotid bifurcation, without craniotomy, by means of a sharpended suture inserted through the external carotid artery (Fig. 1) .
Vascular injury highly correlates with brain edema generally evaluated by brain water content in rat experimental SAH, showing increased intracranial pressure (ICP), and decreased microvascular flow, as well as injury to neuronal tissues [42] [43] [44] . Since 48 h after SAH is the time point at which maximal cerebral vasospasm is observed in rats, the 24-h time point seems to be correct for the analysis of EBI after SAH [45] . Furthermore, understanding EBI has become more and more important than that of CVS itself. Many recent studies using interventions such as: pharmacological agents, transgenic and knockout animals, or hyperbaric oxygen have been used to elucidate the numerous intracellular second messenger cascades and to find a promising treatment for EBI ( Table 1 ).
The Mechanisms of Early Brain Injury After SAH
Perhaps the most immediate event following the rupture of an intracranial aneurysm is an arrest in intracranial circulation, caused by a peak of ICP (rising as high as mean arterial blood pressure within 1 min of ictus). The ICP then falls over several minutes to reach a much lower baseline, but remains higher than normal [128] .
The temporary intracranial circulatory arrest promotes hemostasis and contributes to severe global ischemic injury, all leading to loss of autoregulation, the reduction in cerebral perfusion pressure (CPP), secondary raised ICP, and decreased cerebral blood flow (CBF) [5, 37] . This hypoxic state also culminates in energy failure in neurons and glia, and initiates the cascade of events leading to cytotoxic edema [5] . Ischemia also results in apoptosis of cells that constitute the BBB [129] . Death of endothelial cells and perivascular astrocytes cause increased diffusion of serum from the vascular lumen into cerebral tissues (vasogenic edema). SAH also impacts brain parenchyma by activating astrocytes and microglia, and triggering upregulation of the pro-inflammatory cytokines [130, 131] .
Therefore, factors stemming from the initial bleeding in SAH include: raised ICP, decreases in CBF and CPP, BBB disruption, brain swelling, brain edema, acute vasospasm, and dysfunction of autoregulation, all of which constitute pathophysiological variables occurring during the EBI period (within the first 72 h after SAH) [5] . Acute global ischemia, altered ionic homeostasis, degradation of vascular integrity, excitotoxicity, thrombin activation, oxidative stress, inflammation, elevated matrix metalloproteinase (MMP) 9, and activation of the NO-NOS pathway are all clinically relevant through their involvement in cell death and ultimate dysfunction that follows SAH ( Fig. 2 ) [132] [133] [134] . LDH lactate dehydrogenase, MAPKs mitogen-activated protein kinases, MCP-1 monocyte chemotactic protein-1, MMP matrix metalloproteinase, MP1 microtubule-associated protein 1, MT mortality, NA not applicable, NADPH nicotinamide adenine dinucleotide phosphate, NF-kappaB nuclear factor kappa B, NO nitric oxide, NOS nitric oxide synthase, Nrf2-ARE nuclear factor erythroid 2-related factor 2 and antioxidant responsive element, NS neurological score, PCI pre-chiamatic blood injection model, RBC red blood cell, rCBF regional cerebral blood flow, ROS reactive oxygen species, SHI subarachnoid hemolysate injection model, SIN single blood injection model, siRNA small interfering RNA, SOD superoxide dismutase, TIMP tissue inhibitor of MMP, TNF tumor necrosis factor, VEGF vascular endothelial growth factor, ZO-1 zona occludens 1
Cell Death and Antiapoptotic Therapy in Early Brain Injury After SAH Even a brief ischemic insult to the brain may trigger complex cellular events which lead to progressive apoptotic and necrotic cell death [135] . In general, apoptosis can be regarded as an energy-dependent process whereas necrosis is not. In SAH, if the initial bleed were severe enough to prevent blood flow to the brain as in a global stroke, it is unlikely that the brain tissue would survive. As a result, necrosis is not a major factor in SAH [37] , and apoptosis may play an important role in EBI after SAH. Akt (protein kinase B), a serine/threonine kinase, is one of the key antiapoptotic signaling molecules downstream of phosphoinositide 3-kinase (PI3K) in EBI after SAH [58, 86, 114] . Mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK), c-Jun Nterminal kinase (JNK), and p38, have all been studied in EBI. JNK and p38 are activated in response to inflammatory cytokines and cellular stress, upregulating apoptotic cascades [136] . The tumor suppressor gene, p53, also regulates apoptosis. In EBI after SAH, antiapoptotic therapies have been reported to ameliorate outcomes by targeting the MAPK pathway [38, 61, 78, 93] , activating p53 [12, 60, 92, 106] , and hypoxia inducible factor-1 (HIF-1) target genes by hyperbaric oxygen [137] .
Future Directions of SAH Research
Now, EBI is considered to have a great potential for the implementation of treatment modalities in patients with SAH, attenuating some of the devastating secondary injuries that can be seen in the long term [37] . Mortality should be examined, and neurological functioning ought to be thoroughly evaluated because this information is very important in terms of translation from animals to humans. The mismatch between treatment of angiographical CVS and poor clinical outcome could result from mechanisms other than vasospasm, such as EBI, but also from the use of inadequate animal models of vasospasm. Since both EBI and CVS may contribute to the pathogenesis of delayed neurological deficits, experimental CVS should also be made by mimicking human SAH, in terms of having an injured artery and direct hemorrhagic brain lesion under arterial blood pressure [13] . The endovascular perforation model seems suitable to employ in acute SAH research, as it can produce more severe pathophysiological changes and a comparable insult to a ruptured aneurysm, as opposed to the double blood injection model [138] .
Research regarding EBI after SAH is limited, and further studies are needed to clarify the exact mechanisms involved. Furthermore, it is postulated that cell death mechanisms such as apoptosis, autophagy, necroptosis, and endoplasmic reticulum stress, as well as microcirculatory dysfunction, cortical spreading ischemia, and delayed neuronal injury may also be contributing to the outcomes.
Conclusion
Given the fact that the reversal of CVS does not appear to improve the outcome, it could be argued that the treatment 
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